The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation

Oncology Reports

Volumn 19, Issue 6, 2008, Pages 1477-1483

  Drebber, Uta ^a   Baldus, Stephan E ^b   Nolden, Britt ^a   Grass, Guido ^a   Bollschweiler, Elfriede ^a   Dienes, Hans P ^a   Hölscher, Arnulf H ^a   Mönig, Stefan P ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

C met; Gastric cancer; Immunohistochemistry; P21; P53; Prognosis

Indexed keywords

PROTEIN P21; PROTEIN P53; SCATTER FACTOR RECEPTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1A; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; CORRELATION ANALYSIS; FEMALE; GASTRECTOMY; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; STAINING; STOMACH CARCINOMA; TUMOR DIFFERENTIATION; ADENOCARCINOMA; CELL NUCLEUS; COLLOID CARCINOMA; METABOLISM; METASTASIS; MIDDLE AGED; PAPILLARY CARCINOMA; PATHOLOGY; PROSPECTIVE STUDY; SIGNET RING CARCINOMA; STOMACH TUMOR; SURVIVAL RATE;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; CARCINOMA, PAPILLARY; CARCINOMA, SIGNET RING CELL; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GASTRECTOMY; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-MET; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 48849104457     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Botterweck AA, Schouten LJ, Volovics A, Dorant E and van Den Brandt PA: Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 29: 645-654, 2000.
2. Anderson C, Nijagal A and Kim J: Molecular markers for gastric adenocarcinoma: an update. Mol Diagn Ther 10. 345-352, 2006.
3. Huang TJ, Wang JY, Lin SR, Lian ST and Hsieh JS: Over-expression of the c-met protooncogene in human gastric carcinoma correlation to clinical features. Acta Oncol 40: 638-643, 2001.
4. Monig SP, Zirbes TK, Schroder W, et al: Staging of gastric cancer: correlation of lymph node size and metastatic infiltration. AJR Am J Roentgenol 173: 365-367, 1999.
5. Siewert JR, Bottcher K, Stein HJ and Roder JD: Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 228: 449-461, 1998.
6. Forman D and Burley VJ: Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol 20: 633-649, 2006.
7. Smith MG, Hold GL, Tahara E and El-Omar EM: Cellular and molecular aspects of gastric cancer. World J Gastroenterol 12: 2979-2990, 2006.
8. Vauhkonen M, Vauhkonen H and Sipponen P: Pathology and molecular biology of gastric cancer. Best Pract Res Clin Gastroenterol 20: 651-674, 2006.
9. Zheng L, Wang L, Ajani J and Xie K: Molecular basis of gastric cancer development and progression. Gastric Cancer 7: 61-77, 2004.
10. Liotta LA, Steeg PS and Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336, 1991.
11. Amemiya H, Kono K, Itakura J, et al: c-Met expression in gastric cancer with liver metastasis. Oncology 63: 286-296, 2002.
12. Nakajima M, Sawada H, Yamada Y, et al: The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85: 1894-1902, 1999.
13. Seol DW, Chen Q, Smith ML and Zarnegar R: Regulation of the c-met proto-oncogene promoter by p53. J Biol Chem 274: 3565-3572, 1999.
14. Efeyan A and Serrano M: p53: guardian of the genome and policeman of the oncogenes. Cell Cycle (In press).
15. Lee KE, Lee HJ, Kim YH, et al: Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Jpn J Clin Oncol 33: 173-179, 2003.
16. Xi YG, Ding KY, Su XL, et al: p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. Carcinogenesis 25: 2201-2206, 2004.
17. Roninson IB: Oncogenic functions of tumour suppressor p21(Waf1/Cip1/ Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett 179: 1-14, 2002.
18. Monig SP, Eidt S, Zirbes TK, Stippel D, Baldus SE and Pichlmaier H: p53 expression in gastric cancer: clinicopathological correlation and prognostic significance. Dig Dis Sci 42: 2463-2467, 1997.
19. Baldus SE, Schneider PM, Monig SP, et al: p21/waf1/cip1 in gastric cancer: associations with histopathological subtypes, lymphonodal metastasis, prognosis and p53 status. Scand J Gastroenterol 36: 975-980, 2001.
20. Cervantes A, Rodriguez Braun E, Perez Fidalgo A and Chirivella Gonzalez I: Molecular biology of gastric cancer. Clin Transl Oncol 9: 208-215, 2007.
21. Prat M, Narsimhan RP, Crepaldi T, Nicotra. MR, Natali PG and Comoglio PM: The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int J Cancer 49: 323-328, 1991.
22. Di Renzo MF, Poulsom R, Olivero M, Comoglio PM and Lemoine NR: Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res 55: 1129-1138, 1995.
23. Wu MS, Shun CT, Wang HP, et al: Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection. Gastroenterology 112: 1457-1465, 1997.
24. Carneiro F and Sobrinho-Simoes M: The prognostic significance of amplification and overexpression of c-met and c-erbB-2 in human gastric carcinomas. Cancer 88: 238-240, 2000.
25. Hollstein M, Shomer B. Greenblatt M, et al: Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 24: 141-146, 1996.
26. Tolbert DM, Noffsinger AE, Miller MA, et al: p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status. Mod Pathol 12: 54-60, 1999.
27. Fenoglio-Preiser CM, Wang J, Stemmermann GN and Noffsinger A: TP53 and gastric carcinoma: a review. Hum Mutat 21: 258-270, 2003.
28. Saito H, Osaki T, Murakami D, et al: Prediction of sites of recurrence in gastric carcinoma using immunohistochemical parameters. J Surg Oncol 95: 123-128, 2007.
29. Victorzon M, Nordling S, Haglund C, Lundin J and Roberts PJ: Expression of p53 protein as a prognostic factor in patients with gastric cancer. Eur J Cancer 32A: 215-220, 1996.
30. Ichiyoshi Y, Oiwa H, Tomisaki S, et al: Overexpression of p53 is associated with growth pattern and prognosis in advanced gastric cancer. Hepatogastroenterology 44: 546-553, 1997.
31. McCulloch P, Taggart T, Ochiai A, O'Dowd G, Nash J and Sasako M: c-erbB2 and p53 expression are not associated with stage progression of gastric cancer in Britain or Japan. Eur J Sing Oncol 23: 304-309, 1997.
32. Pinto-de-Sousa J, Silva F, David L, et al: Clinicopathological significance and survival influence of p53 protein expression in gastric carcinoma. Histopathology 44: 323-331, 2004.
33. Grand-Perret T, Cik M, Arts J, et al: Assay development for high throughput screening of p21(Waf1/Cip1) protein expression in intact cells using fluorometric microvolume assay technology. Drugs Exp Clin Res 30: 89-98, 2004.
34. Gamboa-Dominguez A, Seidl S, Reyes-Gutierrez E, et al: Prognostic significance of p21WAF1/CIP1, p27Kip1, p53 and E-cadherin expression in gastric cancer. J Clin Pathol (In press).
35. Seo YH, Joo YE, Choi SK, Rew JS, Park CS and Kim SJ: Prognostic significance of p21 and p53 expression in gastric cancer. Korean J Intern Med 18: 98-103, 2003.